Bertholet Nicolas, Winter Michael R, Cheng Debbie M, Samet Jeffrey H, Saitz Richard
Alcohol Treatment Center, Department of Community Medicine and Health, Lausanne University Hospital, Lausanne, Switzerland
Data Coordinating Center, Boston University School of Public Health, Boston, MA, USA.
Alcohol Alcohol. 2014 Jul-Aug;49(4):423-9. doi: 10.1093/alcalc/agu016. Epub 2014 Apr 15.
Managing patients with alcohol dependence includes assessment for heavy drinking, typically by asking patients. Some recommend biomarkers to detect heavy drinking but evidence of accuracy is limited.
Among people with dependence, we assessed the performance of disialo-carbohydrate-deficient transferrin (%dCDT, ≥1.7%), gamma-glutamyltransferase (GGT, ≥66 U/l), either %dCDT or GGT positive, and breath alcohol (> 0) for identifying 3 self-reported heavy drinking levels: any heavy drinking (≥4 drinks/day or >7 drinks/week for women, ≥5 drinks/day or >14 drinks/week for men), recurrent (≥5 drinks/day on ≥5 days) and persistent heavy drinking (≥5 drinks/day on ≥7 consecutive days). Subjects (n = 402) with dependence and current heavy drinking were referred to primary care and assessed 6 months later with biomarkers and validated self-reported calendar method assessment of past 30-day alcohol use.
The self-reported prevalence of any, recurrent and persistent heavy drinking was 54, 34 and 17%. Sensitivity of %dCDT for detecting any, recurrent and persistent self-reported heavy drinking was 41, 53 and 66%. Specificity was 96, 90 and 84%, respectively. %dCDT had higher sensitivity than GGT and breath test for each alcohol use level but was not adequately sensitive to detect heavy drinking (missing 34-59% of the cases). Either %dCDT or GGT positive improved sensitivity but not to satisfactory levels, and specificity decreased. Neither a breath test nor GGT was sufficiently sensitive (both tests missed 70-80% of cases).
Although biomarkers may provide some useful information, their sensitivity is low the incremental value over self-report in clinical settings is questionable.
对酒精依赖患者的管理包括评估重度饮酒情况,通常是通过询问患者。一些人推荐使用生物标志物来检测重度饮酒,但准确性的证据有限。
在有酒精依赖的人群中,我们评估了去唾液酸糖基化转铁蛋白(%dCDT,≥1.7%)、γ-谷氨酰转移酶(GGT,≥66 U/L)、%dCDT或GGT呈阳性以及呼气酒精含量(>0)在识别三种自我报告的重度饮酒水平方面的表现:任何重度饮酒(女性≥4杯/天或>7杯/周,男性≥5杯/天或>14杯/周)、反复重度饮酒(≥5杯/天且≥5天)和持续重度饮酒(≥5杯/天且连续≥7天)。将有酒精依赖且当前有重度饮酒的受试者(n = 402)转介至初级保健机构,并在6个月后使用生物标志物进行评估,同时采用经过验证的自我报告日历法评估过去30天的酒精使用情况。
自我报告的任何重度饮酒、反复重度饮酒和持续重度饮酒的患病率分别为54%、34%和17%。%dCDT检测任何、反复和持续自我报告的重度饮酒的敏感性分别为41%、53%和66%。特异性分别为96%、90%和84%。对于每种酒精使用水平,%dCDT的敏感性均高于GGT和呼气测试,但检测重度饮酒的敏感性不足(漏诊34 - 59%的病例)。%dCDT或GGT呈阳性可提高敏感性,但未达到令人满意的水平,且特异性降低。呼气测试和GGT的敏感性均不足(两种测试均漏诊70 - 80%的病例)。
尽管生物标志物可能提供一些有用信息,但其敏感性较低,在临床环境中相对于自我报告的增量价值值得怀疑。